Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 21, 2013; 19(47): 8949-8962
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8949
Table 1 Nucleic acid-based anti-hepatitis C virus therapeutics
ClassMode of action TargetStatus
Hairpin ribozymeCleave target RNAs5'-UTR[24,28], 3'-UTR[28], and core region[24]Tested in in vitro[24] and in cell culture model[28]
HDV ribozyme5'-UTR[30]Tested in in vitro
Hammerhead ribozyme (Hepatozyme)5'-UTR[33-35]Completion of phase II
DNAzyme5'-UTR[41], core and NS5B region[39,40]Tested in in vitro and in cell culture model
RNase P5'-UTR[45-47]
Splicing riboymeSelectively replace target RNAs with desirable RNAs5'-UTR[51]
Allosteric ribozymeInhibit HCV replication[54] or cleave HCV RNA[31] through recognizing ligandsmiR-122[54] and 5'-UTR[31]
AptamerBind to target molecule and function as decoys and/or inhibitorsNS3[68-70]
Viral RNA[80,81]
RNAiTarget RNA cleavage or translation inhibition5'-UTR and 3'-UTR[93-96,100-102]
Protein coding regions[103-109]
Antisense oligonucleotideBind to complementary RNAs and suppress the access to cellular machinery, thereby inhibiting expression or function of the targeted RNAs5'-UTR[134-137]Completion of Phase II
AntimiRBlock miRNA activitymiR-122[19,138]Completion of Phase II